In the first quarter, CSPC PHARMA's profit attributable to shareholders was approximately 1.478 billion yuan, a year-on-year decrease of 8.4%
I'm PortAI, I can summarize articles.
CSPC PHARMA announced its Q1 2025 performance, with revenue of approximately RMB 7.015 billion, a year-on-year decrease of 21.9%; profit attributable to shareholders was approximately RMB 1.478 billion, a year-on-year decrease of 8.4%. Revenue from the pharmaceutical business was RMB 5.500 billion, down 27.3%, affected by industry policies. Revenue from raw material products increased by 14.6% to RMB 1.072 billion, with vitamin C sales revenue growing by 25.0%. R&D expenses increased by 11.4% to RMB 1.302 billion, accounting for approximately 23.7% of pharmaceutical business revenue
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments